These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34301030)

  • 1. Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments.
    Almutairy BK; Alshetaili A; Alali AS; Ahmed MM; Anwer MK; Aboudzadeh MA
    Polymers (Basel); 2021 Jul; 13(14):. PubMed ID: 34301030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
    Jain S; Patel K; Arora S; Reddy VA; Dora CP
    Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives.
    Hassan RH; Gad HA; El-Din SB; Shaker DS; Ishak RAH
    Int J Pharm; 2022 Nov; 628():122278. PubMed ID: 36243325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
    Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
    Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs.
    Chai R; Gao H; Ma Z; Guo M; Fu Q; Liu H; He Z
    Curr Drug Deliv; 2019; 16(6):500-510. PubMed ID: 31244438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation.
    Nasr A; Gardouh A; Ghorab M
    Pharmaceutics; 2016 Jun; 8(3):. PubMed ID: 27355963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olmesartan Medoxomil-Loaded Niosomal Gel for Buccal Delivery: Formulation, Optimization, and
    Palei NN; Mohanta BC; Rajangam J; Guptha PM
    Turk J Pharm Sci; 2024 Jul; 21(3):199-210. PubMed ID: 38994813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
    Kaithwas V; Dora CP; Kushwah V; Jain S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():10-20. PubMed ID: 28284054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines.
    Anwer MK; Fatima F; Ahmed MM; Aldawsari MF; Alali AS; Kalam MA; Alshamsan A; Alkholief M; Malik A; Az A; Al-Shdefat R
    Saudi Pharm J; 2022 Jun; 30(6):726-734. PubMed ID: 35812154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
    Nagaraj K; Narendar D; Kishan V
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Sustained Release Baricitinib Loaded Lipid-Polymer Hybrid Nanoparticles with Improved Oral Bioavailability.
    Anwer MK; Ali EA; Iqbal M; Ahmed MM; Aldawsari MF; Saqr AA; Ansari MN; Aboudzadeh MA
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation.
    El-Dahmy RM; Elsayed I; Hussein J; Althubiti M; Almaimani RA; El-Readi MZ; Elbaset MA; Ibrahim BMM
    Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment.
    Albash R; El-Nabarawi MA; Refai H; Abdelbary AA
    Int J Nanomedicine; 2019; 14():6555-6574. PubMed ID: 31616143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation.
    Albash R; Abdelbary AA; Refai H; El-Nabarawi MA
    Int J Nanomedicine; 2019; 14():1953-1968. PubMed ID: 30936696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology.
    Attari Z; Bhandari A; Jagadish PC; Lewis S
    Saudi Pharm J; 2016 Jan; 24(1):57-63. PubMed ID: 26903769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability Enhancement of Olmesartan Medoxomil Using Hot-Melt Extrusion: In-Silico, In-Vitro, and In-Vivo Evaluation.
    Jadhav P; Gokarna V; Deshpande V; Vavia P
    AAPS PharmSciTech; 2020 Sep; 21(7):254. PubMed ID: 32888102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.
    Thakkar HP; Patel BV; Thakkar SP
    J Pharm Bioallied Sci; 2011 Jul; 3(3):426-34. PubMed ID: 21966165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and Characterization of Self-Microemulsifying Drug Delivery System of Olmesartan Medoxomil for Bioavailability Improvement.
    Prajapati ST; Joshi HA; Patel CN
    J Pharm (Cairo); 2013; 2013():728425. PubMed ID: 26555991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment.
    Kamran M; Ahad A; Aqil M; Imam SS; Sultana Y; Ali A
    Int J Pharm; 2016 May; 505(1-2):147-58. PubMed ID: 27005906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Diphenyl carbonate-Crosslinked Cyclodextrin Based Nanosponges for Oral Delivery of Baricitinib: Formulation, Characterization and Pharmacokinetic Studies.
    Aldawsari MF; Alhowail AH; Anwer MK; Ahmed MM
    Int J Nanomedicine; 2023; 18():2239-2251. PubMed ID: 37139486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.